Ct053ptsa Free Base Uses, Dosage, Side Effects and more
Ct053ptsa Free Base is under investigation in clinical trial NCT03758287 (Ct053ptsa Free Base (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative).
| Trade Name | Ct053ptsa Free Base |
| Generic | Ningetinib |
| Ningetinib Other Names | Ct-053 free base, Ct-053-ptsa free base, Ct053ptsa free base |
| Type | |
| Formula | C31H29FN4O5 |
| Weight | Average: 556.594 Monoisotopic: 556.212198213 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
